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Introduction {#s1}
============

Understanding individual exposures and effects is critical in successful epidemiologic investigations to avoid misclassification of exposures or outcomes ([@c3]; [@c42]); however, intra- and inter-person variation in predictors of exposures (e.g., behaviors, microactivity patterns, work- and home-related tasks), genetic susceptibility, and toxicokinetics make quantitative assessment difficult without individual-level data ([@c23]; [@c47]; [@c48]; [@c81]). Biomarkers are useful tools for understanding environmental exposures, susceptibility, and biological responses leading to disease outcomes ([@c10]; [@c57]). Further, the collection of temporally resolved biological samples enables the individual analysis of markers of exposure and disease accounting for this intra- and inter-person variation ([@c10]).

This manuscript describes a comprehensive biomarker approach to enable us to evaluate household air pollution (HAP) exposures, susceptibility, and early effects for a variety of health outcomes as a part of a large randomized controlled trial called the Household Air Pollution Intervention Network (HAPIN) trial. HAPIN was designed to evaluate the effect of a randomized liquified petroleum gas (LPG) stove and fuel intervention on health among family members in 800 households in each of four diverse biomass-using low- and middle-income countries (LMICs; Guatemala, India, Peru and Rwanda) populations using exposure--response (i.e., evaluation of how exposure relates to biomarker or disease outcome) analyses and comparisons between the study arms to which participants were assigned, regardless of their actual adherence to the intended condition. These LMIC locations were purposefully selected to be diverse in characteristics such as altitude, population density, cooking practices, fuel types, and baseline levels of pollution to improve the study's generalizability. Briefly, HAPIN is enrolling 800 eligible pregnant women (at $9\,\text{to} < 20\,\text{weeks}\,\text{gestation}$) at each of the LMIC countries referred to as International Research Collaboration (IRCs) sites and following these women through pregnancy and their child to 1 year of age. In approximately one-fourth of these households, up to 200 older adult women (OAW) are also being enrolled. Households are randomized into control and intervention arms (1:1) with the intervention arm receiving an LPG stove and gas supply for the duration of the study. The primary health outcomes of HAPIN are birth weight, severe pneumonia in the first 12 months of life, stunting at 12 months of age, and blood pressure in the OAW. The study protocol has been reviewed and approved by institutional review boards (IRBs) or ethics committees of all participating institutions. The study has been registered with ClinicalTrials.gov and is overseen by an independent Data Safety Monitoring Board (DSMB). Recruitment and data collection began in May 2018 and expected completion is August 2021. The HAPIN trial is described in more detail elsewhere ([@c21]).

The HAPIN trial is composed of many core components, including exposure assessment \[e.g., particulate matter $\leq 2.5\;\mu m$ in aerodynamic diameter (${PM}_{2.5}$), black carbon measures\], biomarker measurements, stove use monitoring, surveillance, and data management. In particular, one of the aims of HAPIN is to evaluate associations between targeted and untargeted/exploratory biomarkers of exposure and effect with intervention status or exposure defined from personal or household air pollution measurements (detailed in [@c37]). To successfully achieve this aim, we developed a comprehensive biomarker center (BMC) comprising scientists from each IRC and collaborative institutions involved with HAPIN, including experts in exposure science, HAP, analytical chemistry, epidemiology, and toxicology to ensure the most appropriate biomarkers are measured in the most viable and logistically feasible matrix to provide maximum exposure and health information in the HAPIN cohort. In addition, the BMC is supported by two analytical biomarker laboratories: *a*) the Laboratory for Exposure Analysis and Development in Environmental Research (LEADER) at Rollins School of Public Health, Emory University, Atlanta, Georgia; and *b*) the laboratory at Sri Ramachandra Institute of Higher Education and Research (SRIHER), Chennai, India. The overall goal of our BMC is to provide high-capacity, high-quality, and high-throughput analysis of a wide range of biomarkers in samples collected from participants. This entails four primary objectives: *a*) to provide training and monitoring compliance of sample collection, handling, and storage including developing collection and aliquoting protocols, ensuring sample integrity throughout the process and developing a short- and long-term archival system; *b*) to identify, prioritize, and measure specific biomarkers of HAP exposure and effect in urine and dried blood spots (DBS); *c*) to develop local laboratory capacity and harmonize biomarker measures across IRCs; and *d*) to develop and validate novel biomarkers that will provide insight into the broader mechanistic questions linking HAP exposure to disease development.

Rationale for the HAPIN Biomarker Design {#s2}
========================================

HAPIN is a complex and costly study funded by multiple agencies with different missions. Because of this, we sought to collect as many biological matrices as were feasible from both a cost and participant and field staff burden perspective. Thus, we wanted to evaluate biomarkers related to outcomes including cardiovascular, metabolic, cancer, and respiratory disease, as well as birth outcome and child development. This included a detailed prioritization scheme that included strength of evidence linking exposure or outcome and biomarker, our ability to measure the biomarker, and the stability/validation of the biomarker in the specified matrix. With this in mind, we sought out the most viable biomarkers that could comprehensively evaluate the components of HAP exposure and these health outcomes. Furthermore, we wanted to allow for innovation in our design by incorporating cutting-edge biomarkers, including epigenetic alterations and metabolic alterations. Recognizing the field is ever changing and new biomarkers are discovered each year, we also implemented a Biomarker Nomination process whereby newly emerging biomarkers such as fibrinogen and telomeres could be continually included throughout the duration of the study, given financial and laboratory limitations. Although all of the newly nominated biomarkers may not be discussed in this paper, we are working toward formalizing plans for their eventual measurement. Finally, we also had to consider the reality that a minimum of two laboratories would be involved in these measurements because biological samples from India cannot be shipped to another country or analyzed by a non-Indian laboratory (with the exception of small subsets of samples used for cross-validation purposes). This required that we evaluate both the capabilities and capacities of the laboratories, including instrumentation that differed widely. In an ideal scenario, one laboratory would perform all analyses to allow for easy comparison of data between countries. To ensure we would be able to compare data, we developed a thorough quality assurance/quality control scheme that is described in detail below. This scheme extended beyond the laboratories, however, and included metrics of quality and success in field activities that involved collecting the biological specimens. This multifaceted biomarker design required careful planning and coordination to enable successful execution that was continually evaluated for quality and completeness.

Biological Matrix Selection {#s3}
===========================

Because of the large number of participants and the already burdensome exposure, behavioral, and intervention measures in place in the HAPIN trial, we opted for a biospecimen approach that would enable us to maximize the number of appropriate samples collected while minimizing participant burden and risk ([Table 1](#t1){ref-type="table"}). For participating pregnant women, children, and OAW, we chose to collect routine blood samples as DBS on a five-spot Guthrie filter paper card, a method that overcomes collection, transportation, and storage limitations of venipuncture sampling ([@c52]), and to collect a convenience or spot urine sample. The use of DBS is a novel aspect of our study because it also allows us to collect blood from the children, which is often not feasible when venipuncture is required. As such, the measurements of biomarkers that are traditionally measured in whole blood or serum will be validated against DBS measurements. We will use venous blood/DBS pairs collected in the formative pilot phases of our research to ensure these measurements are stable and interpretable. All biomarkers will be similarly validated in one or both of the BMC laboratories. Ideally, serum and DBS measurements are highly correlated. In instances where they are not, we may still have internal validity to use the markers as pre-intervention and post-intervention measures, although the concentrations may not be comparable to clinically interpretable values.

###### 

Biosample collection timeline.

Table 1 has seven columns, namely, child age (study time point); less than 20 weeks gestation (baseline); 24 to 28 weeks gestation (1 to 3 months post-randomization); 32 to 36 weeks gestation or birth (3 to 5 months post-randomization); approximately 3 to 7 months of age (approximately 9 months post-randomization); approximately 6 months of age (approximately 12 months post-randomization); approximately 12 months of age (approximately 18 months post-randomization).

  Child age (study time point)                                          $< 20\,\text{weeks}$ gestation (baseline)   24--28 weeks gestation (1--3 months post-randomization)   32--36 weeks gestation/birth (3--5 months post-randomization)   $\sim 3–7\,\text{months}$ of age ($\sim 9\,\text{months}$ post-randomization)   $\sim 6\,\text{months}$ of age ($\sim 12\,\text{months}$ post-randomization)   $\sim 12\,\text{months}$ of age ($\sim 18\,\text{months}$ post-randomization)                                                                         
  --------------------------------------------------------------------- ------------------------------------------- --------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------ ------------------------------------------------------------------------------- ----- --------- ----- ----- ----- ----- ----- ----- ----- ----- ----- -----
                                                                        PW                                          C                                                         OAW                                                             PW                                                                              C                                                                              OAW                                                                             PW    C         OAW   NM    C     OAW   NM    C     OAW   NM    C     OAW
  Urine                                                                 X                                           ---                                                       X                                                               X                                                                               ---                                                                            X                                                                               X     ---       X     ---   X     X     ---   X     X     ---   X     X
  Dried blood spots                                                     X                                           ---                                                       X                                                               X                                                                               ---                                                                            X                                                                               X     X birth   X     ---   X     X     ---   X     X     ---   X     X
  Oral rinse[^*a*^](#TF2){ref-type="table-fn"}                          ---                                         ---                                                       X                                                               ---                                                                             ---                                                                            ---                                                                             ---   ---       ---   ---   ---   ---   ---   ---   X     ---   ---   ---
  Nasal turbinate sample[^*a*^](#TF2){ref-type="table-fn"}              ---                                         ---                                                       X                                                               ---                                                                             ---                                                                            ---                                                                             ---   ---       ---   ---   ---   ---   ---   ---   X     ---   ---   ---
  Buccal scrape[^*a*^](#TF2){ref-type="table-fn"}                       ---                                         ---                                                       X                                                               ---                                                                             ---                                                                            ---                                                                             ---   ---       ---   ---   ---   ---   ---   ---   X     ---   ---   ---
  Venous blood (RBC, BC and plasma)[^*a*^](#TF2){ref-type="table-fn"}   ---                                         ---                                                       X                                                               ---                                                                             ---                                                                            ---                                                                             ---   ---       ---   ---   ---   ---   ---   ---   X     ---   ---   ---

Note: ---, not applicable; BC, buffy coat; C, child; NM, new mother; OAW, older adult woman; PW, pregnant woman; RBC, red blood cells.

Peru and Guatemala international research collaborating sites only.

Materials for urine collection are dropped off at the home 1 d prior to sample collection so the participants can collect a first morning void sample, record the collection time on the label, and store it in the biospecimen-certified cooler boxes provided. The field staff collect the cooler boxes that morning and transport them back to satellite or central laboratories. These cooler boxes either have refrigerant gel inside the walls such that the entire cooler box is prefrozen or use hard-walled ice packs that are prefrozen. Our experiments indicated that both types of boxes retained sufficient cooling temperature for the 48-h period in which the cooler box was deployed in the field (unpublished data). When field staff arrive, they collect a DBS sample from the pregnant woman and OAW via finger prick after warming the hands and massaging the arms to encourage adequate blood flow for collection. For infants, DBS samples are collected by heel stick until the 6-month visit, after which they are collected via finger prick, consistent with the World Health Organization and American Association for Clinical Chemistry guidelines ([@c83]). For infant urine samples, a pediatric urine collection bag is affixed to the infant's genital area and a urine sample is collected over 2--3 h. We explored the use of disposable diapers for urine collection during the formative research phases of HAPIN where methods, procedures and equipment were pilot tested in the field, and both field staff and parents preferred the more traditional urine collection bag that is used in clinical settings. Likely, this is because diapers are not commonly used in our target populations, so we opted for this more straightforward collection approach. To date, our success rates collecting child urine this way has been high \[i.e., Guatemala 94% (609/646), Rwanda 97% (692/717), Peru 72% (243/336), India 94% (580/614)\]. A field blank (described below) is collected after every 100 urine samples are collected. Additional biosamples are collected from the OAW in Peru and Guatemala to enable the exploration of novel cancer biomarkers ([@c11]; [@c74]) and omics analyses (see details below). For these women, nasal turbinate swabs, an oral rinse, buccal scrapes, and a venous blood draw are obtained. The venous blood samples are collected in serum separator tubes for serum and in ethylenediaminetetraacetic acid-preserved tubes to enable the separation of plasma, buffy coat, and red blood cells for storage and analysis. The venous blood and urine samples are processed and aliquoted in the field laboratories of each IRC within 4 h of collection (or within 8 h if refrigerated). All samples are stored at $- 20{^\circ}C$ at the IRC laboratories for the short term ($\sim 3–7\,\text{months}$) until shipped to Emory University (Peru, Guatemala, and Rwanda samples) or SRIHER (India samples), where they are stored at $- 80{^\circ}C$ until analysis or archival in the biorepository.

Biomarker Selection {#s4}
===================

The biomarkers selected for analysis ([Table 2](#t2){ref-type="table"}) were chosen because of previous links to air pollution/HAP exposure. Moreover, because the four major chronic diseases (i.e., cardiovascular disease, cancer, chronic respiratory disease, and diabetes), which together account for $> 75\%$ of all chronic disease deaths globally, share common pathophysiological mechanisms (e.g., inflammation and oxidative stress) ([@c35]), these markers were considered important to measure.

###### 

Target biomarkers for the HAPIN trial.

Table 2 has six columns, namely, biomarker, biomarker number for Table 2, reason for selection, matrix, method, and method reference.

  Biomarker                                                                                                                                                                                                                                                                                                                                                  Biomarker no. for [Table 2](#t2){ref-type="table"}   Reason for selection                                                           Matrix                 Method          Method reference
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------------------------ ---------------------- --------------- -----------------------------------------------
  Intercellular adhesion molecule 1 (ICAM-1)[^*a*^](#TF4){ref-type="table-fn"}                                                                                                                                                                                                                                                                               1                                                    Endothelial marker of cardiovascular function                                  DBS                    Immunoassay     [@c6]; [@c31]; [@c54], [@c53]
  Vascular cellular adhesion molecule 1 (VCAM-1)[^*a*^](#TF4){ref-type="table-fn"}                                                                                                                                                                                                                                                                           2                                                    Endothelial marker of cardiovascular function                                  DBS                    Immunoassay     [@c54]
  Endothelin-1[^*a*^](#TF4){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                             3                                                    Endothelial marker of cardiovascular function                                  DBS                    Immunoassay     [@c29]
  E-selectin[^*a*^](#TF4){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                               4                                                    Endothelial marker of cardiovascular function                                  DBS                    Immunoassay     [@c6]; [@c54]
  C-reactive protein (CRP)[^*a*^](#TF4){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                 5                                                    Inflammation marker                                                            DBS                    Immunoassay     [@c6]; [@c54], [@c53]
  Interleukin 6 (IL-6)[^*a*^](#TF4){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                     6                                                    Inflammation marker                                                            DBS                    Immunoassay     [@c6]; [@c54]
  von Willebrand factor antigen (vWF)[^*a*^](#TF4){ref-type="table-fn"}                                                                                                                                                                                                                                                                                      7                                                    Blood coagulation protein                                                      DBS                    Immunoassay     [@c6]; [@c49]
  Hemoglobin A1c (HbA1c)[^*a*^](#TF4){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                   8                                                    Marker of glycemic control                                                     DBS, capillary blood   POC, LC-MS/MS   [@c24]; [@c34]
  Hemoglobin (Hb)                                                                                                                                                                                                                                                                                                                                            9                                                    Clinical biomarker                                                             DBS, capillary blood   POC, LC-MS/MS   [@c34]; [@c58]
  Lipids[^*a*^](#TF4){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   10                                                   Clinical biomarkers                                                            DBS                    Immunoassay     [@c1]
  P53 Tumor-associated antigen antibodies (p53 TAA antibodies)[^*a*^](#TF4){ref-type="table-fn"}                                                                                                                                                                                                                                                             11                                                   Lung and other cancer biomarker                                                DBS                    Array assay     [@c88]
  F2-Isoprostanes[^*a*^](#TF4){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                          12                                                   Inflammation markers                                                           DBS                    Immunoassay     [@c76]
  Clara cell protein (CC16)[^*a*^](#TF4){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                13                                                   Lung insult marker                                                             DBS                    Immunoassay     [@c14]
  8-OH-deoxyguanosine (8OHdG)[^*a*^](#TF4){ref-type="table-fn"}                                                                                                                                                                                                                                                                                              14                                                   Oxidative stress marker                                                        Urine                  LC-MS/MS        [@c50]
  Myeloperoxidase (MPO)[^*a*^](#TF4){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                    15                                                   Oxidative stress marker                                                        DBS                    Immunoassay     [@c50]
  Malondialdehyde (MDA)[^*a*^](#TF4){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                    16                                                   Oxidative stress marker                                                        Urine                  LC-MS/MS        [@c40]
  Cytochrome P450 (Cyp450)[^*a*^](#TF4){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                 17                                                   Enzyme induction                                                               DBS                    Immunoassay     [@c43]
  3-OH cotinine; cotinine, and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL)[^*b*^](#TF5){ref-type="table-fn"}                                                                                                                                                                                                                                        18                                                   Short-term and longer-term ($\sim 6\,\text{weeks}$) tobacco smoke biomarkers   Urine                  LC-MS/MS        [@c5]; [@c13]; [@c19]; [@c56]; [@c71]; [@c92]
  Polycyclic aromatic hydrocarbons (1-OH pyrene,1-/2-naphthol, 2-/3-hydroxyfluorine, 2-/3-/4-hydroxyphenanthrene, phenanthrene tetrol)[^*b*^](#TF5){ref-type="table-fn"}                                                                                                                                                                                     19                                                   Carcinogen exposure biomarker                                                  Urine                  GC-MS/MS        [@c4]; [@c61]
  Volatile organic chemicals \[mercapturate metabolites including *S*-phenylmercaptuate (benzene metabolite), *S*-benzylmercapturate (toluene metabolite), *S*-1-phenyl-2-hydroxyethylmercapturate (styrene metabolite), and *S*-2-hydroxyethylmercapturate (acrylonitrile, vinyl chloride, ethylene oxide metabolite)\][^*b*^](#TF5){ref-type="table-fn"}   20                                                   Carcinogen exposure biomarker                                                  Urine                  LC-MS/MS        [@c2]; [@c7]; [@c17]
  Heavy metals/metalloids (lead, mercury, cadmium, arsenic)[^*b*^](#TF5){ref-type="table-fn"}                                                                                                                                                                                                                                                                21                                                   Air pollution exposure, neurotoxicants                                         DBS, urine             ICP-MS          [@c15]; [@c38]; [@c56]; [@c70]; [@c70]
  Levoglucosan[^*b*^](#TF5){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                             22                                                   Wood exposure biomarker                                                        Urine                  LC-MS/MS        [@c55]
  Metabolome[^*c*^](#TF6){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                               23                                                   Biomarker discovery                                                            DBS, serum             HRMS            [@c16]; [@c26]; [@c28]; [@c68]
  microRNA[^*c*^](#TF6){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                 24                                                   Biomarker discovery                                                            NT, plasma             RT-PCR          [@c30]; [@c63]
  mRNA[^*c*^](#TF6){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                     25                                                   Biomarker discovery                                                            NT                     RT-PCR          [@c30]
  DNA methylation[^*c*^](#TF6){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                          26                                                   Biomarker discovery                                                            NT, BC, Buccal         Bead chip       [@c59]
  Oral microbiome[^*c*^](#TF6){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                          27                                                   Biomarker discovery                                                            Oral rinse             16S rDNA        [@c39]
  Novel inflammation cancer markers \[serum amyloid A, soluble tumor necrosis factor receptor 2, chemokine (C-X-C motif) ligand 9 or monokine induced by $\gamma\text{-interferon}$\][^*c*^](#TF6){ref-type="table-fn"}                                                                                                                                      28                                                   Cancer risk evaluation                                                         Plasma                 Immunoassay     [@c73]

Note: BC, buffy coat; buccal, buccal cells; DBS, dried blood spots; GC-MS/MS, gas chromatography-tandem mass spectrometry; HAPIN, Household Air Pollution Intervention Network; HRMS, high resolution mass spectrometry; ICP-MS, inductively coupled plasma-mass spectrometry; LC-MS/MS, liquid chromatography-tandem mass spectrometry; NT, nasal turbinate swab; POC, point-of-care; RT-PCR, reverse transcription--polymerase chain reaction.

Measured in all other adult women.

Measured in all participants including pregnant women, children, and other adult women.

Measured in a subset of samples.

Biomarkers of exposure \[polycyclic aromatic hydrocarbons (PAHs), volatile organic chemicals (VOCs), and levoglucosan\] will be measured in all or a subset of all longitudinally collected urine samples from all participants ([Table 1](#t1){ref-type="table"}). In the OAW, we will measure a suite of biomarkers of endothelial function \[intercellular adhesion molecule 1 (ICAM-1), vascular cellular adhesion molecule 1 (VCAM-1), endothelin-1, E-selectin, von Willebrand factor antigen (vWF)\] ([@c62]), inflammation \[C-reactive protein (CRP), interleukin 6 (IL-6), F2-Isoprostanes\] ([@c27]), blood coagulation (vWF) ([@c84]), oxidative stress {8-hydroxy-deoxyguanosine (8OHdG), peroxidation \[i.e., myeloperoxidase (MPO)\]} ([@c50]), glycemic control/diabetes \[hemoglobin A1C (HbA1c)\] ([@c36]), a marker with specific relevance to lung cancer \[P53 tumor-associated antigen (TAA) antibodies\] ([@c25]; [@c72]), enzyme induction \[cytochrome P450 (Cyp450)\], and a marker of lung insult/inflammation \[Clara cell protein (CC16)\] ([@c14]; [@c86]).

Because this is a large randomized controlled trial, it provides an ideal mechanism for discovery of novel biomarkers of exposure and effects associated with HAP. In collaboration with the National Cancer Institute of the National Institutes of Health, an ancillary study was incorporated that involves additional sample collections in the OAW participants of Peru and Guatemala. These additional samples will be collected among all OAW at baseline and at the visit occurring approximately 12 months after the intervention ($n = 400$ samples; [Table 1](#t1){ref-type="table"}). Novel inflammatory cancer markers will be measured and epigenetic and omics techniques will be used for biomarker discovery. In venous blood, the inflammatory markers serum amyloid A, soluble tumor necrosis factor receptor 2, chemokine (C-X-C motif) ligand 9 or monokine induced by $\gamma\text{-interferon}$ will be evaluated, along with CRP to evaluate lung cancer risk ([@c73], [@c74]). In addition, measurement of mRNA, microRNA (miRNA), DNA methylation, the metabolome, and the microbiome in complementary samples will enable us to gain a better understanding of the response of these measures to exposure and intervention ([@c67]; [@c80]).

Biomarker Measurements {#s5}
======================

Across the course of the study, over 55,000 samples will be collected from participants, so it is not logistically feasible to analyze every biomarker in every sample. Thus, we have developed a biomarker analysis scheme that will enable us to maximize the data collected while still keeping the costs and human resource needs within budgetary constraints ([Table 3](#t3){ref-type="table"}). Our rationale for this measurement scheme relates to the health outcomes evaluated in each participant subset. For example, because cardiovascular outcomes will be assessed in the OAW, most clinical markers of cardiovascular disease will only be measured in those samples. Exposure markers will be measured in all participants, including children for whom direct exposure measurements will not be available. Further, we will measure all analytes in all longitudinal samples of a 5% subsample of the population to finalize our biomarker prioritization scheme. These data will provide information on within- and between-person variability in biomarker concentrations and on estimates for exposure--response that will inform the most efficient analysis scheme (i.e., to maximize the information gained for each sample type and aliquot by determining the number of longitudinal measures needed to efficiently answer our research questions). At minimum, this will include longitudinal measurements collected at baseline and after randomization. This process is currently underway as sample collection continues.

###### 

Biomarker class to be measured in each participant.

Table 3 has five columns, namely, biomarker, biomarker number from Table 2, mother, OAW, and child.

  Biomarker                             Biomarker no. from [Table 2](#t2){ref-type="table"}   Mother   OAW   Child
  ------------------------------------- ----------------------------------------------------- -------- ----- -------
  Cardiovascular/endothelial markers    1--4                                                  ---      X     ---
  Oxidative stress markers              14--16                                                ---      X     ---
  Lipids                                10                                                    ---      X     ---
  HbA1c                                 8                                                     X        X     X
  Hb                                    9                                                     X        ---   X
  Other clinical biomarkers             7, 11, 13, 17                                         ---      X     ---
  Exposure biomarkers                   18--22                                                X        X     X
  Inflammation markers                  5, 6, 12                                              ---      X     ---
  Metabolome (subset)                   23                                                    X        X     X
  Microbiome                            27                                                    ---      X     ---
  miRNA/mRNA                            24--25                                                ---      X     ---
  DNA methylation                       26                                                    ---      X     ---
  Novel inflammation markers (subset)   28                                                    ---      ---   ---

Note: ---, not applicable; Hb, hemoglobin; HbA1c, hemoglobin A1c; OAW, older adult woman.

Clinical Biomarkers in DBS {#s5.1}
--------------------------

To more efficiently use DBS samples for clinical markers, a full spot will be sampled and eluted in $1.5\;{mL}$ phosphate buffered saline (PBS). Portions of this stock extract will be used in each of the biomarker measurements, which will require two aliquots from this same stock to allow for a replicate analysis.

### Endothelial, cardiovascular, inflammation, and oxidative stress (i.e., MPO) markers. {#s5.1.1}

These biomarkers are measured using commercially available multiplexed immunoassays (Meso Scale Discovery Multiplex Immunoassay Reader) with customized V-Plex kits. The PBS extracts are placed in 96-well plates, in duplicate, and prepared according to the standard assay protocol. The resulting reaction products are analyzed on a multiplex plate reader with a full set of calibrants and quality control samples. Values are averaged before reporting. Calculated values of replicates that have differences greater than 20% are repeated or flagged as suspect. Similarly, samples are repeated if the quality control samples indicate a failure of proper measurement. Our current limits of detection (LODs) vary by biomarker but are generally in the low picograms-per-milliliter range with relative standard deviations (RSDs) of $< 15\%$. Our approach is further supported by our preliminary results from a cross-sectional study among Nicaraguan women ($n = 54$) using wood-burning cookstoves. For example, a 25% increase in kitchen ${PM}_{2.5}$ was associated with a 7.4% increase \[95% confidence interval (CI): 0.7, 14.5\] in CRP ([@c91]).

### Hemoglobin and HbA1c. {#s5.1.2}

Hemoglobin (Hb) and HbA1c are measured using a latex-enhanced immunoassay that changes the solution turbidity proportional to the amount of Hb and HbA1c in the sample. Percentage HbA1c is the ratio of HbA1c to Hb. This method is superior to traditional immunoassays because of limited interference, especially by fetal Hb ([@c69]). Although less precise than the immunoassay and other standard reference methods ([@c69]; [@c85]), we will also measure Hb (HemoCue® Hb 201 system, HemoCue® AB) and HbA1c ($A1\text{CNow} + \,\text{system}$, Chek Diagnostics) using point-of-care devices during visits in order to provide immediate results back to the pregnant women (i.e., Hb), children (i.e., Hb at the 6- and 12-month visits), and OAW (i.e., HbA1c) on data forms that they can share with their physicians. We believe that immediately sharing some results is of value to the participants and will help keep them engaged in the study. Our previous results among Honduran primary cooks ($n = 142$) utilized the same point-of-care device to measure HbA1c; when HbA1c cut points were used to define diabetes risk, we observed evidence supporting an association between HAP and prevalent prediabetes/diabetes, for example, the prevalence ratio per interquartile range increase ($84{\,\mu g/m}^{3}$) for 24-h personal ${PM}_{2.5}$ was 1.49 (95% CI: 1.11, 2.01) ([@c65]). Suggestive evidence of a positive association between ${PM}_{2.5}$ and continuously assessed HbA1c was also observed, particularly among women $> 49\,\text{years}$ of age ([@c65]).

### Lipids. {#s5.1.3}

HDL, LDL, cholesterol, and triglycerides will be measured using standard clinical methods (e.g., ultracentrifugation and fractionation of cholesterol) ([@c46]; [@c87]). Evidence linking air pollution and metabolic syndrome or its components such as blood lipid profiles comes mainly from studies of ambient air pollution in high-income countries ([@c20]; [@c22]; [@c45]; [@c51]; [@c89]; [@c90]). However, we estimated positive associations between measures of personal HAP and metabolic syndrome among Honduran women ([@c66]). We did not observe cross-sectional associations between HAP exposure and individual blood lipids, although blood pressure seemed to modify an association between ${PM}_{2.5}$ and total cholesterol ([@c66]).

### Tumor-associated antigen antibodies. {#s5.1.4}

Antibodies associated with the p53 signaling pathway have been associated with respiratory cancers as well as other cancers. A commercially available p53 antibody array will be used that evaluates 196 highly specific antibodies related to the p53 signaling pathway (RayBio® Human p53 enzyme-linked immunosorbent assay kit, RayBiotech). This array contains site-specific and phospho-specific antibodies, enabling evaluation of tyrosine and serine/threonine phosphorylation at specific sites.

### Cytochrome P450 induction. {#s5.1.5}

Cyp450 will be measured using standard spectrophotometry and the ferrous carbon monoxide (CO) difference spectrum, the difference between absorbance at $450\,\text{nm}$ wavelength of totally reduced Cyp450 (artificially bound to CO using sodium dithionite) and the sample. The concentration of Cyp450 in the blood is calculated using the Beer-Lambert law and an average extinction coefficient of $91,000{\, M}^{- 1}/{cm}$.

Other Biomarkers in DBS {#s5.2}
-----------------------

### Heavy metals/metalloids analysis. {#s5.2.6}

Heavy metals/metalloids such as lead, cadmium, and mercury are common air pollutants and constituents of smoke from biomass burning and can be measured in DBS and urine. For DBS, a spot is digested using nitric acid on a heater block to break down the molecular components of the blood and the filter paper. Pedersen et al. ([@c60]) reported essentially quantitative recovery of a variety of metals from DBS. The digested matrix is diluted and injected into the inductively coupled plasma--mass spectrometry (ICP-MS) ([@c38]; [@c71]). Multiple isotopes of each metal are monitored to ensure reliable results. Indium, iridium, lutetium, and rhodium are used as internal standards. The method LODs range from $0.1–0.5\,\text{ng}/{mL}$ with RSDs of $< 10\%$.

### Metabolomics/miRNA in DBS. {#s5.2.7}

In a subset of intervention and control participants, a comprehensive metabolomics analysis will be performed. One blood spot will be dissolved in PBS and subsequently extracted with acetonitrile containing internal standards. Samples are analyzed using liquid chromatography (LC)--high resolution MS, enabling accurate mass calculation. Data are subjected to linear regression and principle component analyses to identify features that are significantly related to exposure status with an initial false discovery rate of 20%. Data are matched to standard metabolomics databases to tentatively identify over 10,000 features (unique mass to charge ratios coupled with retention times). Once these biomarkers are discovered, the specificity and sensitivity will be determined in a validation study. Similarly, miRNA discovery and profiling arrays will be generated in the same subset of DBS using TaqMan technology that is commercially available, and then searches will be performed to identify the miRNA present. miRNAs have recently been shown to be measurable in DBS ([@c63]).

Biomarkers in Urine {#s5.3}
-------------------

### Markers of oxidative stress. {#s5.3.8}

Most oxidative stress biomarkers, with the exception of MPO, are measured in both urine and DBS. 8OHdG and F2-isoprostanes are measured in urine using LC--tandem MS (LC-MS/MS) methods.

### PAH metabolites. {#s5.3.9}

The targeted PAH metabolites are readily excreted in urine and have been shown to be representative of the carcinogenic fraction of air pollution primarily from combustion processes ([@c44]). Because exposure biomarkers integrate exposure routes, the specific routes of exposure that have differential toxicities (i.e., inhalation or ingestion) cannot be determined by the biomarker measurement ([@c8]); however, we anticipate that the inhalational pathway will dominate ingestion and, when coupled with exposure data collected in the field, we should be able to apportion exposure sources. The target PAH metabolites are urinary 1-OH pyrene, 1- and 2-naphthols, and phenanthrene tetrol. The urinary biomarkers 1-OH pyrene and 1- and 2-naphthol are predictive of exposures to the carcinogenic components of PAHs that are mostly fecally excreted (e.g., benzo\[a\]pyrene) rather than excreted in urine ([@c79]). Phenanthrene tetrol is a marker of the diol epoxide metabolic activation pathway and a potential biomarker of lung cancer susceptibility ([@c32]; [@c82]). We will measure PAHs using a method already established in our laboratory ([@c41]). One-half milliliter urine will be aliquoted into a test tube and spiked with isotopically labeled internal standards for automatic recovery correction and normalization of mass spectral data. After homogenization of the matrix, the PAH metabolites will be extracted using a mixed-mode phase solid phase extraction. The extract will be subjected to a derivatization process with diazomethane to protect the polar hydroxyl groups, then the concentrated extract will be analyzed using gas chromatography--tandem MS (GC-MS/MS) ([@c75]). PAH metabolites do not respond well to LC-MS/MS analysis because of the nonspecific loss of water and lack of further fragmentation thus require a derivatization and GC-MS/MS analysis. Each analyte has either separation by time or separation by mass (or both). $\left. \text{Two}\,\text{precursor}\rightarrow\text{product}\,\text{ions} \right.$ (quantification and confirmation ion transitions for MS/MS) are monitored for each analyte and its isotope analog. The LODs for all analytes are $0.1\,\text{ng}/{mL}$ with RSDs of $< 12\%$.

### 3-OH cotinine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, levoglucosan, and VOC metabolites. {#s5.3.10}

We will use methods established or implemented in our lab to measure 3-OH cotinine ([@c13]), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) ([@c18]), levoglucosan ([@c55]), and VOC metabolites ([@c2]; [@c7]). 3-OH cotinine and NNAL are short-term (i.e., 2-d) and long-term (i.e., 6-week) markers, respectively, of exposure to tobacco smoke. Levoglucosan is a specific marker of wood burning. VOC metabolites are detoxification products of glutathione binding of the electrophilic VOCs where the terminal amino acids are cleaved and the cysteine is *N*-acetylated and excreted in urine. Other urinary metabolites are mostly bound to glucuronide or sulfates and require a deconjugation step that involves incubation at physiologic temperature with enzymes that contain $\beta\text{-glucuronidase}$ and/or sulfatase activities. Although this process has been optimized for each method, this is typically performed overnight to ensure quantitative deconjugation of the bound analyte. The urine aliquots (typically from $0.1–1\;{mL}$) are spiked with isotopically labeled internal standards and mixed. They are treated with an acetate buffer at pH 4.5--5 and a glucuronidase/sulfatase enzyme solution and then deconjugated overnight at 37°C. The hydrolysate is extracted using solid phase extraction (utilizing mixed-mode cartridges), and the extracts are concentrated for analysis by high performance LC-MS/MS (HPLC-MS/MS) with electrospray ionization ([@c2]; [@c7]; [@c18]; [@c55]; [@c77]). Similar to our PAH analysis, $\left. \text{two}\,\text{precursor}\rightarrow\text{product}\,\text{ions} \right.$ (quantification and confirmation ion transitions) are monitored for each analyte and its isotope analog. The LODs are in the low picograms-per-milliliter range with RSDs of $< 10\%$.

Biomarkers in Other Biosamples (Peru and Guatemala Only) {#s5.4}
--------------------------------------------------------

### Microbiome/metabolome/mRNA/miRNA in additional tissues. {#s5.4.11}

The oral microbiome, metabolome, mRNA, and miRNA will be measured in a subset of OAW in Peru and Guatemala. S16 rDNA sequencing will be performed on oral rinse samples to obtain microbiome data using established techniques ([@c39]). The samples will have been appropriately preserved with RNAprotect (Qiagen) to stabilize the RNA to enable this analysis. miRNA and mRNA will be analyzed using reverse transcription--polymerase chain reaction ([@c30]) and DNA methylation will be measured using BeadChip technology ([@c59]). Metabolomics will be performed in serum samples, as described above.

Statistical Analysis {#s5.5}
--------------------

Descriptive statistics will be conducted and correlations (Pearson or Spearman, as appropriate) will be obtained for all measured pollutant concentrations with the urinary biomarkers of exposure. We will compare biomarker results between the two arms using a mixed model where the biomarker (or its transformation) is the outcome (either continuous or dichotomous), where each subject who is tested repeatedly has a random intercept, and where the independent variable is the treatment arm. We will also conduct exposure--response analyses where the biomarker is again the outcome of interest and the exposure of interest is ${PM}_{2.5}$. Covariates will include age, sex, body mass index, season, and other potential confounders. In both these types of analyses we will check model assumptions. ${PM}_{2.5}$ will be modeled as continuous or transformed, as well as categorically and via splines. We will use a false discovery rate correction to account for multiple comparisons ([@c12]).

We will then consider our primary and secondary outcomes as the outcomes in biomarker--response regressions in which the biomarkers of exposure are predictors. These mixed model regressions will again include a random intercept for the subject with repeated biomarker measurements and will include both binary (pneumonia/stunting) and continuous outcomes (birthweight, blood pressure). These models will not be restricted to post-intervention data but will include baseline data. We will also consider using the average post-intervention biomarker level as a predictor of outcome in these models. In the case of blood pressure, the outcomes will also be repeated measures in the OAW, although again we may model the average blood pressure after the intervention and also consider an interaction between time and the biomarker of interest. Various function of biomarkers will be used, including as continuous or transformed (e.g., log, square root), as well as categorically, and via restricted cubic splines. Again, we will use a false discovery rate correction to account for multiple comparisons ([@c12]).

Finally, based on results observed in the prior analyses for biomarkers that appear to mediate the effect of ${PM}_{2.5}$ on an outcome, we will consider a mediation analysis in which we attempt to separate out the direct and indirect effects of ${PM}_{2.5}$ exposure ([@c94]; [@c93]). We will use directed acyclic graphs to illustrate the mediations under consideration. The basic idea here is to partition the effect of the exposure on outcome between that which passes through an intermediate variable (the biomarker) and that which has a direct effect on the outcome regardless of the level of the biomarker. Such analyses are a natural complement for biomarkers that are thought to be predicted by the exposure and have an effect on the outcome. For example, if ${PM}_{2.5}$ has an effect on blood pressure, one would want to assess whether that effect is mediated by biomarkers of inflammation.

For the omics analyses, we will utilize the R packages xMSannotator ([@c78]) and xMSpanda (<https://rdrr.io/github/kuppal2/xmsPANDA/>), which were both developed at Emory. xMSpanda is based on linear models for microarray data, partial least squares discriminant analysis, and random forests. We will also conduct multivariable analyses within a linear regression framework, using a false discovery rate correction ([@c12]).

Quality Assurance/Quality Control (Intra- and Inter-Laboratory Validation) {#s6}
==========================================================================

Method Validation {#s6.1}
-----------------

All methods used in the BMC are fully validated before use. Validation parameters include determination of LODs and limits of quantification (LOQs), accuracy, precision, robustness, and analytical specificity. The method LOD is defined as $3s_{0}$ (method $\text{LOQ} = 10s_{0}$), where $s_{0}$ is the standard deviation at zero concentration. Most often this is established as the lowest analytical standard with an average signal-to-noise ratio of 3. In instances where the blank samples contain the target analyte from contamination, the LOD is the $\text{concentration}\, + \, 3s_{0}$. The LOD will be verified visually by analysis of samples spiked at the LOD concentration. Because the LOD is not a static number but, rather, is dynamic, changing over the course of analysis on the basis of the constituents of the sample, the analyst conducting the measurements, the status of the instrument, and so on, and average LODs will be reported for each study. Accuracy will be established using National Institute of Standards Standard Reference Materials (NIST SRMs). In addition, spiked recovery experiments where known concentrations are spiked into matrices and quantified as unknowns will be performed to ensure that accuracy is within 20% of the known value as per U.S. Food and Drug Administration regulations. Precision will be established using quality control pools. A continuing Shewart plot will be used to evaluate precision over time. Both intraday and interday precision will be established. Robustness testing of each method will be performed by intentionally altering at least three parameters of the method to determine the effect on the resulting data. The results of these tests will be used to ensure reliability of the methods. In instances where the quality control fails, analyses will cease until the problem is identified and corrective action is taken. The method performance and quality control of the system will be reestablished before analysis recommences.

Because, by law, Indian biological samples cannot be analyzed outside of India, we are prevented from having all analyses across IRCs performed in a single laboratory. To ensure that we have the most valid results across IRCs, we have embarked on an extensive cross-laboratory validation process for which we have much experience ([@c9]; [@c64]). Both the LEADER laboratory at Emory and the SRIHER laboratory in India are actively validating methods in-house but also exchanging samples to ensure we have suitable method agreement. India does allow a quality control set of samples to be exported to allow for cross-validation ([@c33]). To date, we have cross-validated PAH biomarkers and several of the cardiovascular and endothelial markers with good agreement. This validation process also involves on-site training and evaluation in the analysis of biomarkers. So far, our cross-validation has proven fruitful, enabling us to combine results rather seamlessly. These validation studies are being published elsewhere.

Biorepositories in the United States and India {#s7}
==============================================

We have begun the development and maintenance of a long-term biorepository to store biological specimens in a manner that retains sample integrity and is only linked to identifiable participant data through sample coding. Urine samples are aliquoted into cryovials to enable access to the samples without repeated thaw--refreeze cycles to maintain sample integrity. DBS cards are stored in zip top bags with desiccant pouches to prevent deterioration of samples. The biorepository consists of four secure $- 80{^\circ}C$ freezers linked to a monitoring and alarm system that generates automatically transmitted alarms (via email and phone) when the temperature deviates within 10°C of the target temperature. In the case of freezer failure, a fifth overflow freezer will be used to temporarily house the samples until the freezer is repaired. Regular freezer maintenance (i.e., defrosting and calibrating temperature gauges and alarms) will be performed every 6 months and documented.

The freezers will be fully mapped with each sample location (shelf, box, position) and volume. The map will be retained and updated, as needed, using the OpenSpecimen tracking system. Each freezer will remain locked, with access granted only by the BMC co-directors, in accordance with the study protocol or at the request of the study primary investigators or steering committee. Access to the study samples outside of the current protocol will require a vetting process similar to that of the National Heart, Lung, and Blood Institute (NHLBI) Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) repository. This entails the development of a study protocol and budget that must be reviewed and approved by the HAPIN steering committee as well as all participating IRBs and our DSMB. All procedures for collection, labeling, and storage are compatible with the NHLBI BioLINCC repository. A limited data set will be provided to the NHLBI BioLINCC repository as well.

Metrics of Success {#s8}
==================

In addition to the logistics of sample collection and analysis, we have worked into our BMC scheme several ways to evaluate our mechanisms and measure success. These measures include both field- and laboratory-based evaluations to ensure data collection and sample integrity as well as quality biomarker measurements.

Sample Collection/Biosample Data Collection {#s8.1}
-------------------------------------------

We evaluate the sample collection processes at each IRC one time a year to ensure that field teams are collecting and processing samples according to our standard operating procedures. These evaluations are conducted by two BMC members who are not affiliated with any IRC or field team and who have deep understanding of the protocols and the impact deviations can have on data collection. To do this, the evaluators accompany the field staff on typical participant visits and observe firsthand the specimen collection techniques. If they notice deviations or improper practices, these are corrected quickly and the potentially affected sample identities are recorded. At the end of a visit, an evaluation report is presented to the team, including items to improve adherence to the protocols. On a monthly basis, we monitor various sample collection metrics, including time between urine collection and laboratory processing, the amount of time a sample remains at room temperature prior to freezing, and the number of DBS collected per participant. We discuss these parameters monthly with BMC staff and offer remedies when necessary. We also monitor for missing or nonrecorded information and will have those variables promptly corrected.

Field Blanks {#s8.2}
------------

Field blanks are collected for every 100 participant samples collected to ensure we do not have contamination in the exposure biomarkers. The field blank consists of a purified water sample collected at the location that a urine sample was collected. We use blank spots on the Guthrie filter cards for blanks for DBS samples. These are analyzed alongside participant samples to ensure no field contamination has occurred.

Laboratory Analysis {#s8.3}
-------------------

We perform cross-validation to ensure comparable results across the two laboratories. In addition, we routinely participate in proficiency testing programs (e.g., German External Quality Assessment Scheme, New York State Department of Health Trace Elements Proficiency Testing Program, and the Quebec Multielement External Quality Assessment Scheme), where available, to ensure our data are comparable to other participating laboratories. We also include NIST SRMs in every run for target chemicals that have SRMs. Unfortunately, NIST materials are not available for blood spots, but they can be applied to Guthrie cards and analyzed similarly to unknown samples.

Conclusions {#s9}
===========

We have developed a comprehensive biomarker measurement scheme for the HAPIN study that includes targeted exposure, susceptibility, and effect biomarkers, and we have incorporated an untargeted omics analysis for biomarker discovery. Our biomarker plan includes the largest set of biomarkers measured in a HAP study and includes early markers of disease risk. We have incorporated quality measures to ensure accurate data that are comparable among the two laboratories measuring biomarkers. By combining all of these aspects, we have created a strong biomarker component for the HAPIN study.
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